Mizuho Sees Near-Term Trading Opportunity in Biogen (BIIB) Amid Weakness

Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success

Leerink Partners analyst Geoffrey Porges reduced Aducanumab probability of success and cut his price target on Biogen (NASDAQ: BIIB) price target of $355.00 (from $365.00) after Lilly announced on Wednesday that the EXPEDITION 3 study of solanezumab (sola) in mild Alzheimer's patients did not meet its primary or secondary... More

Sola News Negative for Biogen (BIIB) as Latest in Numerous Failures for the Mechanism - Baird

Baird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB), saying Eli Lilly's Solanezumab failure is a negative for the company.,

Skorney commented, "Lilly's registrational EXPEDITION 3 trial for solanezumab in mild Alzheimer's patients failed. Though some secondary endpoints favored sola, Lilly's admission that... More

Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital

BMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) with shares down on Eli Lilly's solanezumab's failure. The analyst said the news decreases the value of aducanumab's.

Somaiya commented, "We expect BIIB shares to trade down on solanezumab's failure, as we... More

Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)

Today's Pre-Open Stock Movers

Medigus Ltd. (NASDAQ: MDGS) 41.6% HIGHER; announced a distribution agreement in Italy with INNOVAMEDICA S.p.A, a privately owned distributor of minimally invasive medical devices. Under terms of the four-year agreement which will take effect January 1st 2017, INNOVAMEDICA S.p.A. will be required to purchase at least 1M of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement.

Euroseas Ltd. (Nasdaq:... More

Sola Failures Appears 'Near-Perfect' for Biogen (BIIB) - Stifel

Stifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) Eli Lilly's Solanezumab did not meet its primary endpoint in the EXPEDITION3 clinical trial. Solanezumab's near-miss is near-Perfect for Biogen, Shrader said.

Shrader commented, "Solanezumab did not meet its primary endpoint in... More

Forward Pharma (FWP): Reiterating Buy Ahead Of Next Week's Litigation - Leerink

Leerink Partners analyst, Jason Gerberry, reiterated his Outperform rating on shares of Forward Pharma (NASDAQ: FWP) ahead of the interference oral arguments. The analyst is modeling 65% odds to FWP prevailing in its patent interference dispute with Biogen (NASDAQ:... More

Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink

Leerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly (NYSE: LLY) announced that the solanezumab (sola) phase III trial in patients with mild Alzheimers disease failed to meet statistical significance on the primary endpoint and only... More

Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

Biogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.

Biogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure

Biogen (NASDAQ: BIIB) is trading down 1% in pre-open trade following news Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).